FOI_6742

Internal Reference Number: FOI_6742

Date Request Received: 17/08/2022 00:00:00

Date Request Replied To: 31/08/2022 00:00:00

This response was sent via: By Email

Request Summary: Treatment of Haemophilia A

Request Category: Researcher


Question Number 1: In the last three months, how many patients have been treated by your haemophilia centre with the following products? • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Obizur • Refacto AF

Answer To Question 1: This information covers May, June and July 2022. • Advate <5 • Adynovi 0 • Elocta 0 • Esperoct 0 • Factor Eight Inhibitor Bypass Activity (FEIBA) 0 • Hemlibra (standalone) 0 • Hemlibra in combination with any Factor VIII 0 • NovoEight 0 • NovoSeven RT 0 • Obizur 0 • Refacto AF 0

Question Number 2: In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY? • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Obizur • Refacto AF

Answer To Question 2: This information covers May, June and July 2022. • Advate <5 • Adynovi 0 • Elocta 0 • Esperoct 0 • Factor Eight Inhibitor Bypass Activity (FEIBA) 0 • Hemlibra (standalone) 0 • Hemlibra in combination with any Factor VIII 0 • NovoEight 0 • NovoSeven RT 0 • Obizur 0 • Refacto AF 0

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.